tetano
Editor, Senior Moderator
J Hosp Infect. 2016 May 25. pii: S0195-6701(16)30095-0. doi: 10.1016/j.jhin.2016.05.012. [Epub ahead of print]
[h=1]Three-day regimen of oseltamivir for postexposure prophylaxis of influenza in wards.[/h] Ishiguro N[SUP]1[/SUP], Oyamada R[SUP]2[/SUP], Nasuhara Y[SUP]3[/SUP], Yamada T[SUP]4[/SUP], Miyamoto T[SUP]4[/SUP], Imai S[SUP]4[/SUP], Akizawa K[SUP]5[/SUP], Fukumoto T[SUP]5[/SUP], Iwasaki S[SUP]5[/SUP], Iijima H[SUP]6[/SUP], Ono K[SUP]6[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] Inpatients who had been in close contact with patients with influenza were given oseltamivir [75mg capsules once daily for adults or 2mg/kg (maximum of 75mg) once daily for children] for three days as postexposure prophylaxis (PEP). The index patients with influenza were prescribed a neuraminidase inhibitor and were discharged immediately or transferred to isolation rooms. The protective efficacy of oseltamivir for three days was 93% overall [95% confidence interval (CI) 53-99%; P=0.023] and 94% for influenza A (95% CI 61-99%; P=0.017), which is comparable to that of seven- to 10-day regimens of oseltamivir as PEP.
Copyright ? 2016. Published by Elsevier Ltd.
[h=4]KEYWORDS:[/h] Influenza; Oseltamivir; Postexposure prophylaxis
PMID: 27346624 DOI: 10.1016/j.jhin.2016.05.012
[PubMed - as supplied by publisher]
[h=1]Three-day regimen of oseltamivir for postexposure prophylaxis of influenza in wards.[/h] Ishiguro N[SUP]1[/SUP], Oyamada R[SUP]2[/SUP], Nasuhara Y[SUP]3[/SUP], Yamada T[SUP]4[/SUP], Miyamoto T[SUP]4[/SUP], Imai S[SUP]4[/SUP], Akizawa K[SUP]5[/SUP], Fukumoto T[SUP]5[/SUP], Iwasaki S[SUP]5[/SUP], Iijima H[SUP]6[/SUP], Ono K[SUP]6[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] Inpatients who had been in close contact with patients with influenza were given oseltamivir [75mg capsules once daily for adults or 2mg/kg (maximum of 75mg) once daily for children] for three days as postexposure prophylaxis (PEP). The index patients with influenza were prescribed a neuraminidase inhibitor and were discharged immediately or transferred to isolation rooms. The protective efficacy of oseltamivir for three days was 93% overall [95% confidence interval (CI) 53-99%; P=0.023] and 94% for influenza A (95% CI 61-99%; P=0.017), which is comparable to that of seven- to 10-day regimens of oseltamivir as PEP.
Copyright ? 2016. Published by Elsevier Ltd.
[h=4]KEYWORDS:[/h] Influenza; Oseltamivir; Postexposure prophylaxis
PMID: 27346624 DOI: 10.1016/j.jhin.2016.05.012
[PubMed - as supplied by publisher]